

**Table S1 Conditions in immunocompromised patients, for which pneumococcal vaccination is indicated (adapted from RKI vaccine recommendations [1])**

Vaccination against	Category	Indication	Notes on implementation
Pneumococcal diseases	I	<p>Children, adolescents and adults with increased health risks due to an underlying condition:</p> <ol style="list-style-type: none"> <li>1. <b>Congenital or acquired immunodeficiency and immunosuppression</b>, eg.: <ul style="list-style-type: none"> <li>• T-cell deficiency or impaired T-cell function</li> <li>• B-cell or antibody deficiency (eg. hypogammaglobulinemia)</li> <li>• Deficiency or impaired function of myeloid cells (eg. neutropenia, chronic granulomatosis, leucocyte adhesion deficiency, signal transmission defects)</li> <li>• Complement and properdin deficiency</li> <li>• Functional hyposplenism (eg. sickle cell anemia), splenectomy* or anatomical asplenia</li> <li>• Neoplastic diseases</li> <li>• HIV infection</li> <li>• Following bone marrow transplant</li> <li>• Immunosuppressive therapy* (eg. due to organ transplant or autoimmune disease)</li> <li>• Immunodeficiency with chronic kidney failure, nephrotic syndrome or chronic liver failure</li> </ul> </li> <li>2. <b>Other chronic diseases</b>, eg.: <ul style="list-style-type: none"> <li>• Chronic cardiac or pulmonary illnesses (eg. asthma, pulmonary emphysema, COPD)</li> <li>• Metabolic illnesses, eg. diabetes mellitus treated with oral medication or insulin.</li> <li>• Neurological illnesses, eg. cerebral palsy or seizures</li> </ul> </li> <li>3. <b>Anatomical and foreign object-associated risks of pneumococcal meningitis</b>, eg.: <ul style="list-style-type: none"> <li>• Cerebrospinal fluid fistula</li> <li>• Cochlear implant*</li> </ul> </li> </ol> <p>* vaccination before starting therapy or performing the procedure when possible</p>	<ol style="list-style-type: none"> <li>1. Sequential vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by PPSV23 after 6-12 months. The PPSV23 vaccine should only be administered to those aged 2+ **</li> <li>2. In those 16+ to receive 1 dose of PPSV23.** Persons 2-15 years to receive sequential vaccination with PCV13 followed by PPSV23 after 6-12 months.**</li> <li>3. Sequential vaccination with PCV13 followed by PPSV23 after 6-12 months. The PPSV23 vaccine should only be administered to those aged 2+ years.**</li> </ol> <p>** due to the limited duration of the protection given by the PPSV23 vaccination, PPSV23 vaccination should be repeated after at least 6 years.</p>

## References

1. Gemeinsamer Bundesausschuss, Richtlinie des Gemeinsamen Bundesausschusses. über Schutzimpfungen nach § 20i Absatz 1 SGB V. Available from: [https://www.g-ba.de/downloads/62-492-2429/SI-RL\\_2021-03-21\\_iK-2021-04-01.pdf](https://www.g-ba.de/downloads/62-492-2429/SI-RL_2021-03-21_iK-2021-04-01.pdf).